<DOC>
	<DOCNO>NCT02674204</DOCNO>
	<brief_summary>The purpose study examine effect atorvastatin , type statin , change heart among woman undergo breast cancer treatment . Atorvastatin may reduce eliminate harmful effect chemotherapy treatment heart tissue breast cancer patient .</brief_summary>
	<brief_title>STOP Heart Disease Breast Cancer Survivors Trial</brief_title>
	<detailed_description>This placebo-controlled study . It compare effect atorvastatin effect placebo ( inactive substance , , sugar pill ) change heart breast cancer treatment . Participants study approximately year half , study enroll 90 patient . During time , three study visit addition standard care visit . Participants also receive telephone call study staff study intervention follow-up phase check-in . Analyses conduct intention-to-treat basis patient complete third study visit 's Cardiac Magnetic Resonance Imaging .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Newly diagnose stage 13 HER2negative breast cancer ( leave rightsided ) Histologically confirm HER2 , ER , PR status Recommended undergo anthracyclinebased treatment , complete one cycle anthracycline treatment Age minimum 18 year Able willing read , understand , sign inform consent form ( ICF ) medical release form Willing able comply trial protocol followup ECOG performance status 01 ( Karnofsky ≥ 70 % ) Prior use statin medication within past year ; use statin medication eligible statin therapy base 2013 ACC/AHA guideline &gt; 50 year old ; use statin medication eligible statin therapy base 2013 ACC/AHA guideline 4050 year old wish place statin therapy History adverse effect , intolerance , allergic reaction attribute statin medication Current use gemfibrozil , cyclosporine , clarithromycin , itraconazole , erythromycin , hepatitis C protease inhibitor telaprevir , HIV protease inhibitor , colchicine , red yeast rice Current use investigational agent Pregnant intention get pregnant next 18 month . Pregnant woman exclude study atorvastatin lipidlowering agent potential teratogenic abortifacient effect , MRI contraindicate pregnant woman . History diabetes , severe lung disease , renal disease ( creatinine &gt; 1.8 CrCl ≤ 50 mL/min ) , hepatic disease ( AST ALT &gt; 3 time upper normal limit ) Abnormal baseline echocardiogram cardiac MRI ( detection congenital heart disease ; ischemic heart disease ; moderate severe valvular heart disease ; cardiomyopathy ; EF &lt; 55 % ) Previously know diagnosed heart disease ( e.g . congenital ; valvular ; coronary artery disease ; history myocardial infarction acute coronary syndrome ; cardiomyopathy , include infiltrative , hypertensive , hypertrophic , dilate , constrictive pericarditis , cardiomyopathy ) Left ventricular dysfunction ( EF &lt; 55 % ) Prior noncardiac illness estimate life expectancy &lt; 4 year Known active infection HIV Allergy contraindication MRI testing , include claustrophobia , metallic part body prohibit MRI , prior gadolinium contrast reaction , uncontrolled moderate hypertension ( sit blood pressure &gt; 160/95 mm Hg measurement record least 2 occasion ) Concurrent illness opinion investigator would compromise either patient integrity data</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Statin therapy</keyword>
	<keyword>HER2-Negative</keyword>
</DOC>